|Mr. Thomas K. Equels||Exec. Vice Chairman, CEO & Pres||835.28k||N/A||1953|
|Mr. Peter W. Rodino III, J.D.||Exec. Director of Gov.al Relations, Gen. Counsel & Sec.||387.68k||N/A||1951|
|Mr. Adam Pascale||Consultant||291.97k||N/A||1948|
|Mr. Wayne S. Springate||Sr. VP of Operations||N/A||N/A||1971|
|Ms. Ellen Lintal||Chief Accounting Officer||N/A||N/A||N/A|
Hemispherx Biopharma, Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. The company was founded in 1966 and is headquartered in Ocala, Florida.
Hemispherx Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.